TLGY Acquisition Corporation Extends Initial Business Combination Deadline

TLGY Acquisition Corporation (NASDAQ: TLGY) recently filed a Form 8-K with the Securities and Exchange Commission to announce its decision to extend the time frame for completing its initial business combination. The company notified Continental Stock Transfer & Trust Company of its intent to push back the Termination Date by an additional month.

This extension, effective from December 17, 2024, to January 16, 2025, is subject to certain conditions. TLGY Acquisition Corporation’s sponsor or its affiliates or designees deposited $60,000, referred to as the “Extension Deposit,” into the trust account. Consequently, the Termination Date has been prolonged by one month until January 16, 2025.

The move to extend the deadline provides the company with more time to finalize its initial business combination activities. TLGY Acquisition Corporation is working towards meeting the necessary requirements within the revised timeframe.

As per the regulatory filing, TLGY Acquisition Corporation’s Chairman and Chief Executive Officer, Vikas Desai, signed off on the report on behalf of the company on December 16, 2024.

TLGY Acquisition Corporation is categorized as an emerging growth company as defined in Rule 405 of the Securities Act of 1933. The company has not chosen to utilize the extended transition period for complying with new or revised financial accounting standards.

Investors and stakeholders are encouraged to stay tuned for further updates as TLGY Acquisition Corporation progresses towards its strategic objectives.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TLGY Acquisition’s 8K filing here.

About TLGY Acquisition

TLGY Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. It intends to acquire companies in the biopharma or technology enabled business-to-consumer industries worldwide.